裏格爾製藥 RIGL 深 滬
已收盤 02-06 16:00:00 美东时间
34.15
+0.930
+2.80%
華盛通- 最 高35.00
- 今 開33.46
- 成交量 35.39万股
- 最 低 33.46
- 昨 收 33.22
- 總市值 6.20亿
- 52周最高 52.24
- 市盈率 靜 34.54
- 換手率 1.95%
- 52周最低 15.50
- 委 比 -58.28%
- 總股本 1815.13万
- 歷史最高 114.40
- 量 比 1.20
- 振 幅 4.64%
- 歷史最低 6.40
- 每 手 1
- 風險率 9.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rigel Reports Preliminary Q4 2025 Revenue Of $69.8M; Guides 2026 Revenue Of $275M-$290M
Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 millionIn the dose escalation phase of the Phase 1b study of R289
01-12 21:13
Rigel Provides Business Update and 2026 Outlook
Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 million In the dose escalation phase ...
01-12 21:05
Rigel Pharmaceuticals Reports Publication In The Journal Of Hematology & Oncology; 5-Year Data Showing Durable Efficacy And Manageable Safety For REZLIDHIA In R/R mIDH1 AML
Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based regimensRigel advances its
2025-11-17 21:15
美股牛股 | Solid Power飙升超51%！与宝马及三星SDI合作推进全固态电池技术商业化；Lemonade涨超34%
Solid Power飙升超51%！与宝马及三星SDI合作推进全固态电池技术商业化；Lemonade涨超34%，Q3业绩大幅超预期并上调业绩指引>>
2025-11-06 15:10
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
Rigel Pharmaceuticals shares are trading higher after the company reported bett...
2025-11-05 05:53
Rigel Pharmaceuticals Raises FY2025 Sales Guidance from $210.000M-$220.000M to $285.000M-$290.000M vs $281.095M Est
Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $210.000 million-$220.000 million to $285.000 million-$290.000 million vs $281.095 million estimate.
2025-11-05 05:04
Rigel Pharmaceuticals Q3 EPS $1.46 Beats $0.84 Estimate, Sales $69.462M Beat $61.880M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $0.84 by 73.19 percent. This is a 108.57 percent increase over earnings of $0.70 per share
2025-11-05 05:03
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
2025-10-09 10:51
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
2025-10-08 22:19
